MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Funding Opportunities: Pioneers, Architects & Consolidators
Funding: U.S. Federal
*Funding: HHS
*HHS: Contracts, Contractors & Awards
*BARDA: Contracts (IDIQ, GWACS, Etc.), Contractors & Awardees
*Contractors & Awardees: BARDA
BioNTech SE (NASDAQ: BNTX)*
Organization & Developments: BioNTech
Parents
BioNTech SE (NASDAQ: BNTX)*
Children
*Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline.
*BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Eli Lilly and Company, Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant, Fosun Pharma, and Pfizer.
*Comirnaty (COVID-19 vaccine mRNA)
*Expansion of mRNA pipeline beyond COVID-19, including cancer and infectious diseases
*Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.
*Next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases.
*The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals.
202: BioNTech, BMS tout first global data for PD-L1xVEGF bispecific in small cell lung cancer, set phase 3 dose
2020: BioNTech and Fosun Pharma form COVID-19 vaccine strategic alliance in China PDF Version_biontech
2020: BioNTech: Promising Early COVID-19 Data, But Still A Long Way To Go
2020: Buy BioNTech After The Ugly Dip Ends
2020: Coronavirus tracker: FDA fast-tracks Pfizer, BioNTech shots; Ex-FDA chief pokes at Gilead's remdesivir data
2020: Covid Report: Moderna And Other Vaccine Makers Catapult On Key Test
2020: Covid-19 vaccine from Pfizer and BioNTech is strongly effective, data show
2020: Pfizer and BioNTech Ink $1.95 Billion COVID-19 Vaccine Deal with U.S. Government
2020: The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine race
2021: Biontech SE: Mutating COVID Virus And An Evolving Competitive Vaccine Environment
2022: BioNTech Q3 Earnings: Management Tight Lipped On 2023 COVID Vaccine Revenues_ seekingalpha.com
2022: BioNTech SE 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2022: Pfizer 'surprised' by Moderna COVID-19 vaccine patent lawsuit
2023: A Vaccine For Pancreatic Cancer Treatment?_ seekingalpha.com
2023: BioNTech aims to start mRNA vaccine output in Rwanda in 2025_ reuters
2023: BioNTech gets ready to ship first modular factory to Rwanda_
2023: BioNTech Q3 Earnings Review: COVID Revenues Downgrade Makes Prognosis Gloomy_seekingalpha.com
2023: BioNTech Revenue Plunges on Falling Demand for COVID-19 Vaccines
2023: BioNTech: Covid Market Expansion Plus CAR-T Therapy Improvements_seekingalpha.com
2023: BioNTech: Hold Out For More Data (Rating Downgrade)_seekingalpha.com
2023: BioNTech: Not Just Another Jab In The Arm
2023: BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics_ seekingalpha.com
2024: BioNTech and Moderna: A tale of two mRNA developers (BNTX:NASDAQ)
2024: BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time
2024: BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise
2024: BioNTech Q3 Earnings Review: Good Quarter, Strong Promise -- But Still A Hold
2024: BioNTech shares slip as FDA places partial clinical hold on lung cancer study By Investing.com
2024: BioNTech-OncoC4 phase 3 cancer trial under partial hold after varying results reported
2024: BioNTech, Regeneron’s mRNA Cancer Vaccine Combo Clears Phase II in Melanoma
2024: BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward
2024: BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical
2024: BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions
2024: Penn sues BioNTech, seeks ‘full royalty payments’ for COVID-19 vaccine
2024: Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents
2024: Promising BioNTech data on triple negative breast cancer treatment
2025: BioNTech shows off lung cancer survival data behind phase 3 push for red-hot bispecific
2026: Experimental BioNTech lung cancer drug shows high responses in early trial
Jumps
*Key People: BioNTech
Finance & Acquisitions: BioNTech